Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics awarded inducement grants to one newly hired non-executive employee on September 20, 2026: non-qualified stock options covering 13,500 shares with a $8.95 exercise price, plus restricted stock units for 6,750 shares. The awards were made under the company's 2026 Employment Inducement Incentive Award Plan and approved by the Human Capital Management Committee of the Board, comprised solely of independent directors, consistent with Nasdaq Listing Rule 5635(c)(4). Vesting is standard, with 25% at the one-year anniversary and the remainder in monthly (options) or annual (RSUs) installments.
Key figures
- Grant Date
- 2026-09-20
- Options Granted
- 13500
- Rsu Shares Granted
- 6750
- Option Exercise Price Usd
- 8.95
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.